Request a copy

Full Text

• Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell 2017;168:960–76.
• Gonzalez A, Hall MN. Nutrient sensing and TOR signaling in yeast and mammals. EMBO J 2017;36:397–408.
• Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10:457–68.
• Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110:163–75.
• Sarbassov DD, Ali SM, Kim D-H, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296–302.
• Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg € MA, Hall A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004;6:1122–8.
• Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4:648–57.
• Duran RV, Hall MN. Regulation of TOR by small GTPases. EMBO Rep 2012;13:121–8.
• Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidicacid-mediated mitogenic activation of mTOR signaling. Science 2001;294: 1942–5.
• Fang Y, Park IH, Wu AL, Du G, Huang P, Frohman MA, et al. PLD1 regulates mTOR signaling and mediates Cdc42 activation of S6K1. Curr Biol 2003;13:2037–44.
• Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 2009;27:S43–51.
• Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.
• Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004;431:200–5.
• Villar VH, Nguyen TL, Delcroix V, Teres S, Bouchecareilh M, Salin B, et al. mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation. Nat Commun 2017; 8:1–12.
• Villar VH, Nguyen TL, Teres S, Bodineau C, Duran RV. Escaping mTOR inhibition for cancer therapy: tumor suppressor functions of mTOR. Mol Cell Oncol 2017;4:e1297284.
• Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 2016;534:272–6.
• Egorov M, Delpech B, Aubert G, Cresteil T, Garcia-Alvarez MC, Collin P, et al. A concise formation of N-substituted 3,4-diarylpyrroles-synthesis and cytotoxic activity. Org Biomol Chem 2014;12:1518–24.
• Kashman Y, Koren-Goldshlager G, Gravalos G, Schleyer M. Halitulin, a new cytotoxic alkaloid from the marine sponge Haliclona tulearensis. Tetrahedron Lett 1999;40:997–1000.
• Collin P, Egorov M, Delpech B, Bakala J, Achab M, Bignon J, et al. N-substituted 3,4-bis(catechol)pyrrole compounds, and the preparation and use thereof in the treatment of cancer. Francepatent WO2014/ 060366. 2014.
• Verdonk ML, Mortenson PN, Hall RJ, Hartshorn MJ, Murray CW. Proteinligand docking against non-native protein conformers. J Chem Inf Model 2008;48:2214–25.
• Veverka V, Crabbe T, Bird I, Lennie G, Muskett FW, Taylor RJ, et al. Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene 2008;27:585–95.
• Surpateanu G, Iorga BI. Evaluation of docking performance in a blinded virtual screening of fragment-like trypsin inhibitors. J Comput Aided Mol Des 2012;26:595–601.
• Colas C, Iorga BI. Virtual screening of the SAMPL4 blinded HIV integrase inhibitors dataset. J Comput Aided Mol Des 2014;28:455–62.
• Martiny VY, Martz F, Selwa E, Iorga BI. Blind pose prediction, scoring, and affinity ranking of the CSAR 2014 dataset. J Chem Inf Model 2016;56:996–1003.
• Selwa E, Martiny VY, Iorga BI. Molecular docking performance evaluated on the D3R grand challenge 2015 drug-like ligand datasets. J Comput Aided Mol Des 2016;30:829–39.
• Selwa E, Elisee E, Zavala A, Iorga BI. Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations. J Comput Aided Mol Des 2018; 32:273–86.
• Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 2013;29:845–54.
• Jorgensen WL, Schyman P. Treatment of halogen bonding in the OPLS-AA force field: application to potent anti-HIV agents. J Chem Theory Comput 2012;8:3895–901.
• Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys 1984;81:3684–90.
• Essmann U, Perera L, Berkowitz ML, Darden T, Hsing L, Pedersen LG. A smooth particle mesh Ewald method. J Chem Phys 1995;103: 8577–93.
• Hess B. P-LINCS: a parallel linear constraint solver for molecular simulation. J Chem Theory Comput 2008;4:116–22.
• Domanski J, Beckstein O, Iorga BI. Ligandbook: An online repository for small and drug-like molecule force field parameters. Bioinformatics 2017;33:1747–9.
• Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheese-man JR, et al. Gaussian 09, Rev: D01. Pittsburgh, PA: Gaussian, Inc.; 2009.
• Jencks WP, Regenstein J. Handbook of biochemistry-selected data for molecular biology. 1st ed. Sober HA, editor. Cleveland: The Chemical Rubber Co.; 1968.
• Villar VH, Merhi F, Djavaheri-Mergny M, Duran RV. Glutaminolysis and autophagy in cancer. Autophagy 2015;11:1198–208.
• Edwards SR, Wandless TJ. The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem 2007;282:13395–401.
• Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010;141:290–303.
• Kim SG, Hoffman GR, Poulogiannis G, Buel GR, Jang YJ, Lee KW, et al. Metabolic stress controls mTORC1 lysosomal localization and dimer-ization by regulating the TTT-RUVBL1/2 complex. Mol Cell 2013; 49:172–85.
• Sun Y, Fang Y, Yoon M-S, Zhang C, Roccio M, Zwartkruis FJ, et al. Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad Sci U S A 2008;105:8286–91.
• Muckerman JT, Skone JH, Ning M, Wasada-Tsutsui Y. Toward the accurate calculation of pKa values in water and acetonitrile. Biochim Biophys Acta - Bioenerg 2013;1827:882–91.
• Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation by the rapamycin-binding domain. Nature 2013;497:217–23.
• National Cancer Institute. Everolimus. Rockville, MD: National Cancer Institute; 2013. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/fda-everolimus
• McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 2017;168:613–28.
• Aits S, Jaattela M. Lysosomal cell death at a glance. J Cell Sci 2013; 126:1905–12.
• Yoon M-S, Rosenberger CL, Wu C, Truong N, Sweedler J V, Chen J. Rapid mitogenic regulation of the mTORC1 inhibitor, DEPTOR, by phosphatidic acid. Mol Cell 2015;58:549–56.
• Henkels KM, Miller TE, Ganesan R, Wilkins BA, Fite K, Gomez-Cambronero J. A phosphatidic acid (PA) conveyor system of continuous intracellular transport from cell membrane to nucleus maintains EGF receptor homeostasis. Oncotarget 2016;7:47002–17.